Amendment to the Claims

Please amend the claims as follows, without prejudice or disclaimer. This claim listing replaces all prior claim listings.

- 1-66. Cancelled.
- 67. (Currently amended) An isolated peptide of claim 36, the peptide being selected from the group consisting of LMDMQTFKA (SEQ ID NO.:7), SEQ ID NO.:8. SEQ ID NO.:9, SEQ ID NO.:11, SEQ ID NO.:12, SEQ ID NO.:21, SEQ ID NO.:24, SEQ ID NO.:24, SEQ ID NO.:29, SEQ ID NO.:30, SEQ ID NO.:32, SEQ ID NO.:34, SEQ ID NO.:37, SQYSGQLKV (SEQ ID NO.:38), SEQ ID NO.:40, SEQ ID NO.:49, SEQ ID NO.:51, SEQ ID NO.:54, SEQ ID NO.:57, SEQ ID NO.:59, SEQ ID NO.:61, SEQ ID NO.:63, SEQ ID NO.:67, and ELCSVRLTL (SEQ ID NO.:70), SEQ ID NO.:72, SEQ ID NO.:74, SEQ ID NO.:77, SEQ ID NO.:78, SEQ ID NO.:81, SEQ ID NO.:84, and SEQ ID NO.:85, the peptide being immunogenic as determined by ELISPOT analysis of human T-cell cultures or human T cell cytotoxicity assay.
- 68, Cancelled,
- 69. (Previously presented) A composition comprising an isolated peptide of claim 67 and a pharmaceutically acceptable carrier.
- 70-72. Cancelled.
- 73. (New) An isolated peptide having the amino acid sequence LMDMQTFKA (SEQ ID NO.:7).
- 74. (New) A composition comprising the isolated peptide of claim 73 in a pharmaceutically acceptable carrier.
- 75. (New) A composition for inducing an immune response in a host comprising the isolated peptide of claim 73 and at least one isolated peptide selected from the group consisting of SEQ ID NO.:8, SEQ ID NO.:9, SEQ ID NO.:11, SEQ ID NO.:12, SEQ ID NO.:21, SEQ ID NO.:24, SEQ ID NO.:28, SEQ ID NO.:29, SEQ ID NO.:30, SEQ ID NO.:32, SEQ ID NO.:34, SEQ ID NO.:37, SEQ ID NO.:38, SEQ ID NO.:40, SEQ ID NO.:49, SEQ ID NO.:51, SEQ ID NO.:54, SEQ ID NO.:57, SEQ ID NO.:59, SEQ ID NO.:61, SEQ ID NO.:63, SEQ ID NO.:67, SEQ ID NO.:70, SEQ ID NO.:72, SEQ ID NO.:74, SEQ ID NO.:77, SEQ ID NO.:78, SEQ ID NO.:81, SEQ ID NO.:84, SEQ ID NO.:85, SEQ ID NO.:85, SEQ ID NO.:99, SEQ ID NO.:100, SEQ ID NO.:101, SEQ ID

- NO.:102, SEQ ID NO.:103, and SEQ ID NO.:104, and a pharmaceutically acceptable carrier.
- 76. (New) A method for inducing an immune response in a host comprising administering to the host the isolated peptide of claim 73.
- 77. (New) A method for inducing an immune response in a host comprising administering to the host the composition of claim 74.
- 78. (New) A method for inducing an immune response in a host comprising administering to the host the composition of claim 75.